An interventional study of Folic Acid and 5-MTHF (5-methyltetrahydrofolate) in Folate, Folate Bioavailability and Clinical Trials, sponsored by University of British Columbia. Not yet recruiting. Open to female participants aged 19 Years to 42 Years. Per ClinicalTrials.gov, last updated 2024-10-21.
Sponsored by University of British Columbia · Not applicable, Interventional, and Treatment
A study to help understand what forms of folic acid are most effective to increase folate status during pregnancy for the best protection against neural tube defects
A multisite randomized controlled trial to determine whether supplementation with (6S)-5-methyltetrahydrofolic acid (5-MTHF) is at least as effective as synthetic folic acid in increasing maternal folate status for protection against neural tube defects (NTDs).
University of British Columbia is the lead sponsor of 1,335 studies on the registry; 256 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
5MTHF
Dietary Supplement: 5-MTHF (5-methyltetrahydrofolate)
Folic acid
Dietary Supplement: Folic Acid
folic acid (0.6 mg)
0.625 mg/d (6S)-5-MTHF
RBC folate
•Maternal RBC folate concentrations (nmol/L)
Time frame: At 6 (± 2) wks gestation (approximate time of neural tube closure)
Maternal plasma placental growth factor (pg/mL)
A novel biomarker with increasing use in clinical practice due to a discriminatory capacity for fetal growth restriction vs a small, but healthy fetus
Time frame: At 18 (± 1) and 30 (± 1) wks gestation
Human milk total folate concentrations
Unmetabolized folic acid, reduced folate forms (nmol/L), and folate binding protein
Time frame: At 4 weeks postpartum
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2025; primary completion for Jan 2029, 48 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levomefolic acid
University of British Columbia →